By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – BG Medicine today began trading shares of its stock on the Nasdaq under ticker symbol "BGMD."

The company is offering 5 million shares of its stock at $7 per share, for potential proceeds of $35 million. Lazard Capital Markets is serving as the sole book-running manager for the offering. Baird and Cowen and Company are co-managers.

The underwriters have a 30-day option to purchase up to 750,000 shares to cover over-allotments, if any.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.